In contrast, PSMA-targeting alpha-particle therapy (TAT) has only been evaluated in few preclinical experiments, preliminary dosimetry attempts and some retrospective observational studies, yet. First clinical
2025年2月,东诚药业集团公司吴晓明副总经理及新加坡国立大学陈小元教授、张静静教授团队在《European Journal of Nuclear Medicine and Molecular Imaging》期刊上正式发表名为“Development of [225Ac]Ac‑LNC1011 for targeted alpha-radionuclide therapy of pr...
Anju Wadhwa 2, Adam Oskowitz 3, Bin Liu 4, Brian W. Miller 5, Kai Vetter 1, Robert R. Flavell 2,6* & Youngho Seo 1,2* Radiopharmaceutical therapy using α-emitting 225Ac is an emerging treatment for patients with advanced metastatic cancers. Me...
[5]Khreish, Fadi et al. “225Ac-PSMA-617/177Lu-PSMA-617 tandem therapy of metastatic castration-resistant prostate cancer: pilot experience.” European journal of nuclear medicine and molecular imaging vol [6]Kratochwil, Clemens et al. “Targeted ...
225Ac-PSMA is one of the novel theragnostic alpha endoradiotherapy agents under investigation for salvage therapy in metastatic castration resistant prostate cancer (mCRPC). We present a case of hormone naïve patient with high-volume metastatic, symptomatic prostate cancer involving the lungs. The ...
Targeted −therapy of metastatic castration-resistant prostate cancer with 225Ac-PSMA-617: Swimmer-plot analysis suggest efficacy regarding duration of tumor control. J Nucl. Med. 2018; 9:795-802. [2] Predictors of overall and disease free survival in metastatic castration-resistant prostate ...
European Journal of Nuclear Medicine and Molecular Imaging (2019) 46:1988 https://doi.org/10.1007/s00259-019-04401-9 CORRECTION Correction to: 225Ac-PSMA-617 in chemotherapy-naive patients with advanced prostate cancer: a pilot study Mike Sathekge1 & Frank Bruchertseifer2 & Otto Knoesen3 &...
et al. 225Ac-PSMA-617 for PSMA-targeted α-radiation therapy of metastatic castration-resistant prostate cancer. J. Nucl. Med. 57, 1941–1944 (2016). Article CAS Google Scholar Jiang, Z., Revskaya, E., Fisher, D. R. & Dadachova, E. In vivo evaluation of free and chelated ...
177Lu-Labeled prostate-specific membrane antigen radioligand therapy of metastatic castration-resistant prostate cancer: safety and efficacy J. Nucl. Med. (2016) L. Emmett et al. Lutetium-177 PSMA radionuclide therapy for men with prostate cancer: a review of the current literature and discussion ...
Targeted actinium-225 in vivo generators for therapy of ovarian cancer. Cancer Res. 2003;63(16):5084–90. Burstein HJ. The distinctive nature of HER2-positive breast cancers. N Engl J Med. 2005;353(16):1652–4. https://doi.org/10. 1056/NEJMp058197. Cai Z, ...